Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients Based on "Guideline for Re-examination of New Drugs"

NCT03776123 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03776123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03776123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients Based on "Guideline for Re-examination of New Drugs"
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
May 15, 2019
Completion date
March 26, 2024
Enrollment
347 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid carcinoma, hepatocellular carcinoma, renal cell carcinoma